MUC1 Expression Is Essential For Establishment Of Acute Myeloid Leukemia In Vivo

Dina Stroopinsky(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Turner Kufe(Beth Israel Deaconess Medical Center), Akriti Kharbanda(Harvard University), Maxwell Coll, Hasan Rajabi(Harvard University), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Palmer Kristen(Beth Israel Deaconess Medical Center), Neeharika Srivastava(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), Pier Paolo Pandolfi(University of Turin), James D. Levine(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center)
Blood
November 15, 2013
10.1182/blood.v122.21.3787.3787
Cited by 0

Related Papers

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k